Heart Failure With Reduced Ejection Fraction Hfref clinical trials

Explore recruiting heart failure with reduced ejection fraction hfref clinical trials.

Recruiting heart failure with reduced ejection fraction hfref studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart Failure With Reduced Ejection Fraction Hfref trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (OPRA-HF)

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Spain, France, Poland, Germany, Greece, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Sweden, Spain, Hungary, Italy, Denmark, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

Portugal

Phase III and phase IV (Integrated) EU CTIS Study details

Use of determination of drug levels to optimize pharmacotherapy of heart failure

Czechia

Therapeutic use (Phase IV) EU CTIS Study details

Heart Failure With Reduced Ejection Fraction Hfref trials by city

Heart Failure With Reduced Ejection Fraction Hfref in Toronto Heart Failure With Reduced Ejection Fraction Hfref in Vancouver Heart Failure With Reduced Ejection Fraction Hfref in Montreal Heart Failure With Reduced Ejection Fraction Hfref in Calgary Heart Failure With Reduced Ejection Fraction Hfref in Edmonton Heart Failure With Reduced Ejection Fraction Hfref in Ottawa Heart Failure With Reduced Ejection Fraction Hfref in Winnipeg Heart Failure With Reduced Ejection Fraction Hfref in Quebec City Heart Failure With Reduced Ejection Fraction Hfref in Hamilton Heart Failure With Reduced Ejection Fraction Hfref in Kitchener Heart Failure With Reduced Ejection Fraction Hfref in London Heart Failure With Reduced Ejection Fraction Hfref in Halifax Heart Failure With Reduced Ejection Fraction Hfref in New York Heart Failure With Reduced Ejection Fraction Hfref in Los Angeles Heart Failure With Reduced Ejection Fraction Hfref in Chicago Heart Failure With Reduced Ejection Fraction Hfref in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease